Tsinyegoe me kansa ƒe dɔléleŋutete fia alesi dɔlélea wɔna tsinae.
Tsinyegoe me kansa nye nutete vɔ̃ɖi aɖe si dona tso tsinyegoe me lãmenugbagbevi siwo le ŋutsuwo ƒe aɖuɖɔtoƒe te.
Tsinyegoe me tsi si nye spermatozoa ƒe tsi si naa nuɖuɖu eƒe tsinyegoea eye wòkplɔa tsinyegoea yia teƒe bubuwo la tsoa eme.
Womenya nusi tututu gbɔ tsinyegoe me kansa tsona o, gake wonya be nu geɖe gbɔe wòtsona be dɔlélea tea ŋu dzea ame dzi.
Esiawo dometɔ aɖewoe nye ƒe si ame xɔ, ƒome si me wòdzɔ tso, ameƒomevi si wònye, kple domenyiŋusẽfianu aɖewo ƒe tɔtrɔ.
Tsinyegoe me kansa bɔ ɖe ŋutsu tsitsiwo me wu, eye ŋutsu siwo xɔ wu ƒe 65 koŋue léa dɔ sia.
Gakpe ɖe eŋu la, ŋutsu siwo ŋu tsinyegoe me kansa le le woƒe ƒomea me ate ŋu alé dɔ sia bɔbɔe, abe Afrikatɔ siwo le Amerika kple Carib-ƒukpowo dzi tɔwo ene.
Tsinyegoe me kansa ƒe dɔléle nye lãmenugbagbevi siwo le tsinyegoe me ƒe tsitsi kple mamã si ŋu womete ŋu le naneke wɔm le o.
Esia ate ŋu adzɔ le esi domenyiŋusẽfianuwo ƒe tɔtrɔ si naa lãmetsi aɖewo tsina kabakaba alo nana be domenyiŋusẽfianu siwo léa nutete ɖe nu me ƒe dɔwɔwɔ nu tsia anyi ta.
Nɔnɔmetɔtrɔ siawo ate ŋu ana lãmenugbagbeviwo natsi kabakaba, si ana woadze nutete.
Ne nutete la le tsitsim la, ate ŋu ava ge ɖe lãmeka kple ŋutinu siwo te ɖe eŋu me, abe aɖuɖɔtoƒe, asrã, kple lãmeka siwo te ɖe eŋu ene.
Le go aɖewo me la, kansa me nugbagbeviwo ate ŋu ado le nutete gbãtɔa me eye woakaka ɖe ŋutilã ƒe akpa bubuwo to ʋukawo alo lãmekawo me, eye esiae woyɔna be nutete.
Ne kansa la kaka vɔ la, eƒe dɔdamɔnuwo sesẽna wu.
Lãmetsiwo hã ate ŋu akpɔ ŋusẽ ɖe tsinyegoe me kansa dzi, vevietɔ lãmetsi si nye testosterone.
Lãmetsi si nye testosterone ate ŋu ana tsinyegoe me kansa ƒe lãmenugbagbeviwo natsi, eye dɔdamɔnu geɖe siwo wozãna ɖe tsinyegoe me kansa ŋu la ƒe taɖodzinue nye be woana lãmetsi sia ƒe agbɔsɔsɔ dzi naɖe akpɔtɔ alo axe mɔ ɖe eƒe dɔwɔwɔ nu.
Kpuie ko la, tsinyegoe me kansa ƒe dɔléle nye lãmenugbagbevi siwo le tsinyegoe me ƒe tsitsi kple mamã si ŋu womete ŋu le naneke wɔm le o, eye domenyiŋusẽfianuwo, lãmetsiwo, kple nutome ƒe nɔnɔmewo kpɔa ŋusẽ ɖe edzi.
Dɔlélea ƒe dɔwɔwɔ nyuie le vevie be woate ŋu awɔ atike nyuiwo atsɔ adae ahana tsinyegoe me kansa lélawo ƒe nɔnɔme naka ɖe eme.
Zobniw CM, Causebrook A, Fong MK: Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer. Res Rep Urol. 2014, 6 (): 97-105.
Lim HY, Agarwal AM, Agarwal N, Ward JH: Recurrent epistaxis as a presenting sign of androgen-sensitive metastatic prostate cancer. Singapore Med J. 2009, 50 (5): e178-80.
Kohli M, Qin R, Jimenez R, Dehm SM: Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer. Adv Urol. 2012, 2012 (): 781459.
Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995, 1 (9): 944-9.
Msaouel P, Nandikolla G, Pneumaticos SG, Koutsilieris M: Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer. Expert Opin Investig Drugs. 2013, 22 (11): 1385-400.
Kotani K, Sekine Y, Ishikawa S, Ikpot IZ, Suzuki K, Remaley AT: High-density lipoprotein and prostate cancer: an overview. J Epidemiol. 2013, 23 (5): 313-9.
Jadvar H: Molecular imaging of prostate cancer: a concise synopsis. Mol Imaging. , 8 (2): 56-64.
['Mɔxeɖenu: atikewɔwɔ']
['Taɖodzinu siwo nye nufiafia kple nyatakaka koe le nyatakakadzraɖoƒe sia ŋu eye menye atikewɔwɔ ŋuti ɖaŋuɖoɖo alo dɔwɔnawo ƒe nya gblɔm wole o.']
['Mele be woazã nyatakaka siwo wona la atsɔ ada dɔléle alo dɔ aɖe o, eye ele be amesiwo di be yewoakpɔ atikewɔwɔ ŋuti ɖaŋuɖoɖo na yewo la nabia ɖɔkta si xɔ mɔɖegbalẽ.']
['De dzesii be neural network si wɔa nyabiabiawo ƒe ŋuɖoɖowo la meɖia o vevietɔ ne wotsɔ xexlẽdzesiwo wɔe. Le kpɔɖeŋu me, ne wotsɔ ame siwo ŋu dɔléle aɖe le ƒe xexlẽme wɔ dɔe.']
['Bia wò ɖɔkta alo lãmesẽdɔwɔla bubu si dze ƒe aɖaŋuɖoɖo ɣesiaɣi le lãmesẽkuxi aɖe ŋu. Mègaŋe aɖaba ƒu aɖaŋuɖoɖo si ɖɔktawo ɖo na wò alo gbɔ dzi ɖi le exexlẽ me le nyatakakadzraɖoƒe sia ta o. Ne èsusu be ɖewohĩ lãmesẽkuxi aɖe le fu ɖem na ye la, ke yɔ 911 alo yi ɖe afisi wokpɔa nɔnɔme kpatawo gbɔ le.']
['Copyright: Copyright']
['Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the DMCA) na mɔ siwo dzi copyright ƒe nunɔlawo ate ŋu ato awɔ nu ɖe nu siwo wo xɔ se be wo le Internet dzi la ŋu.']
['Ne èxɔe se kple kakaɖedzi be nyatakakadzraɖoƒe alo dɔwɔnu aɖe si míetsɔ wɔ míaƒe nyatakakadzraɖoƒea alo dɔwɔnawo la nye dada le wò gome la, wò ŋutɔ (alo wò dɔtɔ) ate ŋu aŋlɔ agbalẽ aɖo ɖe mí abia be míaɖe nyatakakadzraɖoƒea alo dɔwɔnua ɖa alo axe mɔ ɖe ezazã nu.']
['Ele be woana nyatakakawo to e-mail dzi (kpɔ "Kpekpeɖeŋunaƒe" ƒe akpa si nye e-mail adrɛs). ']
['DMCA bia be nàŋlɔ nyatakaka siwo gbɔna ɖe wò nyatakaka si nèŋlɔ be woada le copyright dzi la me: (1) nuŋɔŋlɔ si fia be copyright le dɔ si ŋu wole nu ƒom le la ŋu; (2) nyatakaka si fia be nuŋɔŋlɔa le eme eye wòade mía nu be míake ɖe eŋu; (3) nyatakaka siwo ana míake ɖe ŋuwò, siwo dometɔ aɖewoe nye wò adrɛs, kaƒodzesi kple e-mail adrɛs; (4) wò nya si fia be èxɔe se kple kakaɖedzi be copyright ƒe ame si tɔe nyatakakaa nye, alo eƒe dɔtɔ, alo se aɖeke meɖe mɔ ɖe eŋu o; ']
['(5) Wò ŋutɔ nàŋlɔ agbalẽ si dzi nàde asii, si me nàde se be ne mèwɔe o la, àda alakpa, atsɔ aɖo kpe edzi be nyatakaka siwo le nyatakakaa me la de pɛpɛpɛ eye be ŋusẽ le asiwò be nàʋli agbalẽ siwo ŋu wogblɔ le be woda le la ta.']
['Eye (6) ame si tɔe agbalẽa nye alo ame si wona ŋusẽe be wòawɔ dɔ le ame si tɔ ŋkɔ me la ƒe asinuŋɔŋlɔ alo eƒe asinuŋɔŋlɔ si le mɔ̃ dzi. ']
['Ne mèŋlɔ nyatakaka siwo katã le etame ɖe agbalẽa me o la, ate ŋu ana be wò nyatoƒoe me dzodzro natsi megbe.']
['Kadodo']
['Taflatse ɖo email ɖe mí ne nyabiabia alo aɖaŋuɖoɖo aɖe le asiwò.']
What is pathophysiology of prostate cancer?
The pathophysiology of prostate cancer refers to the underlying mechanisms and processes that lead to the development and progression of the disease.
Prostate cancer is a malignant tumor that arises from the cells of the prostate gland, which is a small, walnut-shaped organ located below the bladder in men.
The prostate gland produces seminal fluid, which nourishes and transports sperm.
The exact cause of prostate cancer is not fully understood, but several factors are known to increase the risk of developing the disease.
These include age, family history, race, and certain genetic mutations.
Prostate cancer is more common in older men, with the majority of cases occurring in men over the age of 65.
Additionally, men with a family history of prostate cancer are at an increased risk, as are African American men and men of Caribbean descent.
The pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland.
This can occur due to genetic mutations that lead to the overexpression of certain growth factors or the inactivation of tumor suppressor genes.
These mutations can result in the unregulated growth of cells, leading to the formation of a tumor.
As the tumor grows, it can invade nearby tissues and organs, such as the bladder, rectum, and nearby lymph nodes.
In some cases, cancer cells can break away from the primary tumor and spread to other parts of the body through the bloodstream or lymphatic system, a process known as metastasis.
Once the cancer has spread, it can be more difficult to treat.
Prostate cancer can also be influenced by hormonal factors, particularly the androgen hormone testosterone.
Testosterone can stimulate the growth of prostate cancer cells, and many treatments for prostate cancer aim to reduce the levels of this hormone or block its effects.
In summary, the pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland, which can be influenced by genetic, hormonal, and environmental factors.
Understanding the underlying mechanisms of the disease is crucial for developing effective treatments and improving outcomes for patients with prostate cancer.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Le Eŋu']
['BioMedLib zãa kɔmpiuta siwo wɔa dɔ le wo ɖokui si (mɔ̃ siwo zãa mɔ̃ɖaŋunuwo tsɔ srɔ̃a nu) tsɔ wɔa nyabiabia kple ŋuɖoɖowo.']
